BA058-SC: Completed Phase III enrollment

Radius completed enrollment of 2,400 patients in a double-blind, placebo-controlled, international Phase III trial comparing 80 µg BA058-SC daily vs. 20 µg teriparatide daily. BA058-TD, a transdermal formulation of BA058-SC, is in Phase II testing to treat osteoporosis in postmenopausal women. Ipsen granted Radius exclusive rights to BA058 outside of Japan, where Teijin has rights (see BioCentury, Dec. 19, 2005). ...